Global COVID-19 Inactivated Vaccine Market Size, Status and Forecast 2022

In 2021, the global COVID-19 Inactivated Vaccine market size will be US$ million and it is expected to reach US$ million by the end of 2027, with a CAGR of % during 2021-2027.
This report focuses on the global COVID-19 Inactivated Vaccine status, future forecast, growth opportunity, key market, and key players. The study objectives are to present the COVID-19 Inactivated Vaccine development in North America, Europe, Japan, China, Southeast Asia, India, etc.

Global COVID-19 Inactivated Vaccine Scope and Market Size
COVID-19 Inactivated Vaccine market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global COVID-19 Inactivated Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.


Segment by Type
In Clinical Trials
Out-of-Clinical Trials


Segment by Application
Hospital
Clinic
Other


By Region
North America
Europe
Japan
China
Southeast Asia
India


By Company
Inovio Pharmaceuticals
Takis Biotech (Evvivax)
Zydus Cadila
Codagenix, Inc.
GeoVax, Inc.
Bravovax
Janssen Pharmaceutical Companies
Altimmune
Vaxart
CanSino Biologics
ExpreS2ion Biotechnologies ApS
Clover Biopharmaceuticals
GSK
Vaxil Bio Ltd.
Generex
Novavax, Inc.
Sanofi Pasteur
Baylor
iBio, Inc.
Moderna, Inc.
Curevac
ImmunoPrecise